RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing down

The biotech news these days is dom­i­nat­ed by star­tups and big mon­ey, but the cau­tion­ary tales still keep com­ing. 

XTu­it Phar­ma­ceu­ti­cals had banked on the ideas of some of the most promi­nent sci­en­tists en­gaged in drug de­vel­op­ment, re­lied on a sea­soned biotech ex­ec as CEO and had sol­id back­ing from some mar­quee in­vestors like Po­laris and NEA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER